AMENDMENTS TO THE CLAIMS

1-40. (Canceled).

41. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound having the formula:



wherein A is a C_{1-6} saturated or C_{2-6} unsaturated hydrocarbon skeleton, said skeleton being unsubstituted or having between 1 and 10 substituents, inclusive, independently selected from cyano, halo, azido, oxo, and Q_1;

each Q_1 is independently selected from OR_1, SR_1, SO_2R_1, OSO_2R_1, NR_2R_1, $NR_2(CO)R_1$, $NR_2(CO)(CO)R_1$, $NR_4(CO)NR_2R_1$, $NR_2(CO)OR_1$, $(CO)OR_1$, $O(CO)R_1$, $(CO)NR_2R_1$, and $O(CO)NR_2R_1$;

each of R_1, R_2, R_4, R_5, and R_6 is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{6-10} aryl, C_{6-10} haloaryl, C_{6-10} hydroxyaryl, C_{1-3} alkoxy-C_6 aryl, C_{6-10} aryl-C_{1-6} alkyl, C_{1-6} alkyl-C_{6-10} aryl, C_{6-10} haloaryl-C_{1-6} alkyl, C_{1-6} alkyl-C_{6-10} haloaryl, (C_{1-3} alkoxy-C_6 aryl)-C_{1-3} alkyl, C_{2-9} heterocyclic radical, C_{2-9} heterocyclic radical-C_{1-6} alkyl, C_{2-9} heteroaryl, and C_{2-9} heteroaryl-C_{1-6} alkyl;

each of D and D' is independently selected from R_3 and OR_3, wherein R_3 is H, C_{1-3} alkyl, or C_{1-3} haloalkyl;

n is 0 or 1;

E is R_5 or OR_5;

G is O, S, CH_2, or NR_6;

each of J and J' is independently H, C_{1-6} alkoxy, or C_{1-6} alkyl; or J and J' taken together are $=CH_2$ or –O-(straight or branched C_{1-5} alkylene)-O-;

Q is C_{1-3} alkyl;

T is ethylene or ethenylene, optionally substituted with $(CO)OR_7$, where R_7 is H or C_{1-6} alkyl;

each of U and U' is independently H, C_{1-6} alkoxy, or C_{1-6} alkyl; or U and U' taken together are $=CH_2$ or –O-(straight or branched C_{1-5} alkylene)-O-;

X is H or C_{1-6} alkoxy;

each of Y and Y' is independently H or C_{1-6} alkoxy; or Y and Y' taken together are =O, $=CH_2$, or –O-(straight or branched C_{1-5} alkylene)-O-; and

each of Z and Z' is independently H or C_{1-6} alkoxy; or Z and Z' taken together are =O, $=CH_2$, or –O-(straight or branched C_{1-5} alkylene)-O-;

or a pharmaceutically acceptable salt thereof.

42. (Previously Presented) The pharmaceutical composition of claim 41, wherein n is 0.

43. (Previously Presented) The pharmaceutical composition of claim 41, wherein each of D and D' is independently selected from R_3, C_{1-3} alkoxy, and C_{1-3} haloalkyloxy.

44. (Previously Presented) The pharmaceutical composition of claim 41, wherein R_5 is selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{6-10} aryl, C_{6-10} haloaryl, C_{6-10} hydroxyaryl, C_{1-3} alkoxy-C_6 aryl, C_{6-10} aryl-C_{1-6} alkyl, C_{1-6} alkyl-C_{6-10} aryl, C_{6-10} haloaryl-C_{1-6} alkyl, C_{1-6} alkyl-C_{6-10} haloaryl, (C_{1-3} alkoxy-C_6 aryl)-C_{1-3} alkyl, C_{2-9} heterocyclic radical, C_{2-9} heterocyclic radical-C_{1-6} alkyl, C_{2-9} heteroaryl, and C_{2-9} heteroaryl-C_{1-6} alkyl.

45. (Previously Presented) The pharmaceutical composition of claim 41, wherein A comprises a C_{1-6} saturated or C_{2-6} unsaturated hydrocarbon skeleton, said skeleton having at least one substituent selected from cyano, halo, azido, oxo, and Q_1;

each Q_1 is independently selected from OR_1, SR_1, SO_2R_1, OSO_2R_1, NR_2R_1, $NR_2(CO)R_1$, and $O(CO)NR_2R_1$;

n is 0;

G is O;

J and J' taken together are $=CH_2$;

Q is methyl;

T is ethylene;

U and U' taken together are $=CH_2$;

X is H;

each of Y and Y' is H; and

Z and Z' taken together are =O or $=CH_2$.

46. (Previously Presented) The pharmaceutical composition of claim 41, wherein each Q_1 is independently selected from OR_1, SR_1, SO_2R_1, OSO_2R_1, $NH(CO)R_1$, $NH(CO)(CO)R_1$, and $O(CO)NHR_1$;

each R_1 is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_6 aryl, C_6 haloaryl, C_{1-3} alkoxy-C_6 aryl, C_6 aryl-C_{1-3} alkyl, C_{1-3} alkyl-C_6 aryl, C_6 haloaryl-C_{1-3} alkyl, C_{1-3} alkyl-C_6 haloaryl, (C_{1-3} alkoxy-C_6 aryl)-C_{1-3} alkyl, C_{2-9} heterocyclic radical, C_{2-9} heteroaryl, and C_{2-9} heteroaryl-C_{1-6} alkyl;

one of D and D' is methyl or methoxy, and the other is H;

n is 0;

G is O;

J and J' taken together are $=CH_2$;

Q is methyl;

T is ethylene;

U and U' taken together are $=CH_2$;

X is H;

each of Y and Y' is H; and

Z and Z' taken together are =O.

47. (Previously Presented) The pharmaceutical composition of claim 45, wherein A has at least one substituent selected from hydroxyl, amino, azido, halo, and oxo.

48. (Previously Presented) The pharmaceutical composition of claim 47, wherein A comprises a saturated hydrocarbon skeleton having at least one substituent selected from hydroxyl, amino and azido.

49. (Previously Presented) The pharmaceutical composition of claim 48, wherein A has at least two substituents independently selected from hydroxyl, amino, and azido.

50. (Previously Presented) The pharmaceutical composition of claim 48, wherein A has at least two substituents independently selected from hydroxyl and amino.

51. (Previously Presented) The pharmaceutical composition of claim 48, wherein A has at least one hydroxyl substituent and at least one amino substituent.

52. (Previously Presented) The pharmaceutical composition of claim 48, wherein A has at least two hydroxyl substituents.

53. (Previously Presented) The pharmaceutical composition of claim 48, wherein A comprises a C_{2-4} hydrocarbon skeleton.

54. (Previously Presented) The pharmaceutical composition of claim 48, wherein A comprises a C_3 hydrocarbon skeleton.

55. (Previously Presented) The pharmaceutical composition of claim 53, wherein A has an (S)-hydroxyl on the carbon atom alpha to the carbon atom linking A to the ring containing G.

56. (Previously Presented) The pharmaceutical composition of claim 45, wherein A comprises a C_{1-6} saturated hydrocarbon skeleton having at least one substituent selected from hydroxyl and cyano.

57. (Previously Presented) The pharmaceutical composition of claim 46, wherein Q_1 is independently selected from OR_1, SR_1, SO_2R_1, and OSO_2R_1 where each R_1 is independently selected from C_{1-6} alkyl, C_{1-6} haloalkyl, C_6 aryl, C_6 haloaryl, C_{1-3} alkoxy-C_6 aryl, C_6 aryl-C_{1-3} alkyl, C_{1-3} alkyl-C_6 aryl, C_6 haloaryl-C_{1-3} alkyl, C_{1-3} alkyl-C_6 haloaryl, and (C_{1-3} alkoxy-C_6 aryl)-C_{1-3} alkyl.

58. (Previously Presented) The pharmaceutical composition of claim 41, comprising a compound of the following structure



or a pharmaceutically acceptable salt thereof.

59. (Currently Amended) The pharmaceutical composition of claim 41, comprising a compound of the following structure





or a pharmaceutically acceptable salt thereof.

60. (Previously Presented) The pharmaceutical composition of claim 41, further comprising a pharmaceutically-acceptable carrier.

61. (Previously Presented) The pharmaceutical composition of claim 41, further comprising one or more other pharmaceutically-active agents.

62. (Previously Presented) The pharmaceutical composition of claim 61, wherein the one or more other pharmaceutically-active agents is selected from the group consisting of anti-tumor agents, immune-stimulating agents, interferons, cytokines, anti-MDR agents, and anti-angiogenesis agents.

63. (Currently Amended) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is formulated for administration by oral, topical, parenteral, intramuscular, or intravenous routes, or administration by injection or inhalation.

64. (Previously Presented) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is a controlled-release formulation.